Back to search

University of Thessaly (UTH)

Επίδραση της από του στόματος χορηγούμενης πραβαστατίνης στην επίπτωση της σχετιζόμενης με τον αναπνευστήρα πνευμονίας και στη θνητότητα στη ΜΕΘ

Abstract

dc:description

Ventilator associated pneumonia (VAP) has been associated with considerable costs of hospitalization and morbidity. Several strategies have been introduced to minimize the risk of VAP and to improve the outcome in critical care patients. The aim of this study is to investigate whether the use of pravastatin reduces the incidence of VAP and whether it is related with favourable outcomes in critical care patients. The present is a two-centre, two-arms, randomized open label controlled trial. Consecutive patients were recruited from the intensive care unit (ICU) of two hospitals of central Greece. Patient inclusion criteria included mechanical ventilation and ICU stay > 48 hours. The two arms consisted of treatment plus oral pravastatin sodium 40 mg (PG) (n=71 patients) and treatment without pravastatin (CG) (n=81 patients). Treatment was initiated after randomization and ended 30 days later. Among patients studied, sixteen patients (22.5%) in the PG and 28 (34.5%) in the CG (p=0.11) presented pneumonia during the 30-day treatment period in ICU. PG patients with APACHE score ≥15 had marginally increased probability of being free of VAP compared to controls during the 30-day treatment period (p=0.06) and significantly increased probability during the total stay in the ICU (p=0.04). Six patients (8.45%) in the PG and 16 (19.85%) in the CG died during the 30-day treatment period (p=0.06), whereas 10 patients (14.1%) in PG and 24 (29.1%) patients in CG died during the total stay in the ICU (p=0.03). PG patients with APACHE score ≥15 had significantly increased probability of survival compared to controls, during the 30-day treatment period (p=0.04) and marginally increased probability during the total stay in the ICU (p=0.06). Conclusively, this study provides evidence that pravastatin may affect favourably the outcome of critical care patients.

Degree

thesis:*
Grantor dc:publisher
University of Thessaly (UTH)
Year dc:date
2012

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Manoulakas, Efstratios
  • Μανουλάκας, Ευστράτιος

Subjects

dc:subject × 14

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/29247

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Manoulakas, Efstratios; Μανουλάκας, Ευστράτιος. Επίδραση της από του στόματος χορηγούμενης πραβαστατίνης στην επίπτωση της σχετιζόμενης με τον αναπνευστήρα πνευμονίας και στη θνητότητα στη ΜΕΘ. University of Thessaly (UTH), 2012. http://hdl.handle.net/10442/hedi/29247